BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29858758)

  • 21. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
    Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
    Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitude of BRCA1/2 mutation carriers towards fertility preservation, family planning and preimplantation genetic testing for primary prevention of breast and ovarian cancer in the next generation.
    Nahshon C; Lavie O; Oron G
    J Assist Reprod Genet; 2023 Dec; 40(12):2835-2842. PubMed ID: 37751121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis.
    Michaan N; Leshno M; Cohen Y; Safra T; Peleg-Hasson S; Laskov I; Grisaru D
    Reprod Biol Endocrinol; 2021 Oct; 19(1):153. PubMed ID: 34620184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population.
    Riahi A; Gourabi ME; Chabouni-Bouhamed H
    Breast Cancer; 2016 Sep; 23(5):807-12. PubMed ID: 26476744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants.
    Vuković P; Peccatori FA; Massarotti C; Miralles MS; Beketić-Orešković L; Lambertini M
    Crit Rev Oncol Hematol; 2021 Jan; 157():103201. PubMed ID: 33333149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
    Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
    J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
    El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
    Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gronwald J; Glass K; Rosen B; Karlan B; Tung N; Neuhausen SL; Moller P; Ainsworth P; Sun P; Narod SA; Lubinski J; Kotsopoulos J;
    Fertil Steril; 2016 Mar; 105(3):781-785. PubMed ID: 26698676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
    Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
    Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer.
    Menon U; Harper J; Sharma A; Fraser L; Burnell M; ElMasry K; Rodeck C; Jacobs I
    Hum Reprod; 2007 Jun; 22(6):1573-7. PubMed ID: 17428877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
    Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.